You are here

Article Text

Article menu
Download PDFPDF
Letter
Statin therapy and gastric cancer death
  1. Shih-Wei Lai1,2,
  2. Yu-Hung Kuo3,
  3. Kuan-Fu Liao4,5
  1. 1 College of Medicine, China Medical University, Taichung, Taiwan
  2. 2 Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan
  3. 3 Department of Research, Taichung Tzu Chi Hospital, Taichung, Taiwan
  4. 4 College of Medicine, Tzu Chi University, Hualien, Taiwan
  5. 5 Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan
  1. Correspondence to Dr Kuan-Fu Liao; kuanfuliaog{at}gmail.com

http://dx.doi.org/10.1136/postgradmedj-2019-136994

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Statins are commonly used for the treatment of hypercholesterolaemia. The association between statin use and gastric cancer risk has been extensively assessed.1 2 Recently, a cohort study in UK conducted by Spence et al revealed that statin use after a diagnosis of gastric cancer was associated with a lower hazard of cancer-specific death (HR=0.83, 95% CI 0.74 to 0.93).3 This result was partially compatible with that of a cohort study in Republic of Korea showing that statin use for more than 6 months was associated with increased survival rate of gastric cancer compared with non-use (HR=0.168, 95% CI 0.032 to 0.881).4 In order to test the …

    View Full Text

    Footnotes

    • Contributors S-WL contributed to the conception of the article, initiated the draft of the article and approved the final draft submitted. Y-HK and K-FL conducted the data analysis.

    • Funding This study was supported in part by the Ministry of Health and Welfare in Taiwan (MOHW108-TDU-B-212-133004) and China Medical University Hospital in Taiwan (DMR-107-192 and DMR-108-089), Academia Sinica Stroke Biosignature Project (BM10701010021), and MOST Clinical Trial Consortium for Stroke (MOST 108-2321-B-039-003). These funding agencies did not influence the study design, data collection and analysis, decision to publish or preparation of the manuscript.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Ethics approval Insurance reimbursement claims data used in this study were available for public access. Patient identification numbers had been scrambled to ensure confidentiality. Patient informed consent was not required. This study was approved by the Research Ethics Committee of China Medical University and Hospital in Taiwan (CMUH-104-REC2-115).

    • Provenance and peer review Not commissioned; internally peer reviewed.